top of page


Here are a few examples of our publications, collaborations, and discoveries.

Full list of publications can be found here.


Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy

Discovery of a new treatment targeting muscle stem cells that is more effective than the current gold-standard treatment for DMD (glucocorticoids)


An engineered multicellular stem cell niche for the 3D derivation of human myogenic progenitors from iPSCs

Description of an optimized 3D protocol to generate iPSC-derived myoblasts


Clearance of defective muscle stem cells by senolytics reduces the expression of SASP and restores myogenesis in myotonic dystrophy type 1

Discovery that muscle stem cells are defective in DM1 and could be targeted as a therapeutic approach.


Biallelic variants in the transcription factor PAX7 are a new genetic cause of myopathy

Discovery of a new genetic myopathy (named MYOSCO) that reveals a new class of "muscle stem cell myopathies"


EGFR-Aurka Signaling Rescues Polarity and Regeneration Defects in Dystrophin-Deficient Muscle Stem Cells by Increasing Asymmetric Divisions

Discovery of new therapeutic approaches targeting defective muscle stem cells in DMD


Fibro-adipogenic progenitors in skeletal muscle homeostasis, regeneration and diseases

Comprehensive review on the key role of FAPs in skeletal muscle.


Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division

Discovery that muscle stem cells are intrinsically defective in DMD


Transient neonatal exposure to hyperoxia, an experimental model of preterm birth, leads to skeletal muscle atrophy and fiber type switching

Discovery that environmental changes (transient hyperoxia) induce long-term muscle defects.


The adhesion G-protein-coupled receptor Gpr116 is essential to maintain the skeletal muscle stem cell pool

Discovery of a new receptor regulating muscle stem cell quiescence.

bottom of page